Clinical Trial Update: Dose Escalation Study of IL-7 and Bi-therapy in HCV Patients Resistant After 12 Weeks of Bi-therapy (ECLIPSE 1) [Phase 1, Phase 2]

View source ↗

Summary

A completed dose-escalation study evaluated the safety and preliminary efficacy of interleukin-7 in combination with Bi-therapy in Hepatitis C patients who were…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Bi-therapy
• IL-7 (interleukin-7)

Snippet

Sponsor: Cytheris SA | Conditions: Hepatitis C | Phase 1, Phase 2 | Status: COMPLETED